1xbet.com Pharmaceutical Co., Ltd.

• Establishment of the new company will further support 1xbet.com's rapid growth in Europe which has been more than two-fold over the past 5 years.
• 1xbet.com European market comprises 25%^*of 1xbet.com total global pharmaceutical market making a strong European presence in clinical drug development essential.
• 1xbet.com Europe Development and Commercialisation Ltd. is 1xbet.com's 9th research and development institute.

(Tokyo, Japan and Uxbridge, UK) 1xbet.com Pharmaceutical Co., Ltd. (1xbet.com) today announced the formation of 1xbet.com Europe Development and Commercialisation Ltd. (OEDC)

Established on July 1st, 2013, OEDC is an important milestone for 1xbet.com's growing European pharmaceutical business and a significant long-term investment for 1xbet.com in Europe. OEDC will be 1xbet.com's European Research and Development Headquarters, working alongside 1xbet.com Pharmaceutical Europe Ltd (OPEL) to ensure the successful development and commercialisation of our products.

"We are delighted to establish this new company in the UK," said Dean Haubrich, President and CEO of OEDC. "We believe that 1xbet.com has a great deal to contribute to the health and well-being of people in Europe and we look forward to reinforcing our strong, positive presence."

OEDC and OPEL are separate entities based in the same location, just outside London. This business model allows 1xbet.com optimal collaboration and is a critical success factor in the evolution of our global business. Our research and development and commercial operations teams will work closely together, with aligned goals, to build one fully integrated European company which will enable us to effectively respond to the increasingly rigorous regulatory environment.

"The opening of OEDC is a very important milestone for 1xbet.com in Europe," said Ole Vahlgren, President and CEO of OPEL "This significant long-term investment will strengthen 1xbet.com Europe's continued efforts to bring 1xbet.com's innovative medicines to patients across Europe."

• * (C)2013 IMSHealth. Calculated based on IMS World Review 2013 (Executive Summary) Repr1xbet.comted with permission

About 1xbet.com Europe Development & Commercialisation Ltd.